Membrane Fusion Mediated Targeted Cytosolic Drug Delivery Through scFv Engineered Sendai Viral Envelopes

2015 ◽  
Vol 15 (4) ◽  
pp. 386-400 ◽  
Author(s):  
M. Kumar ◽  
P. Mani ◽  
P. Pratheesh ◽  
S. Chandra ◽  
M. Jeyakkodi ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Membrane Fusion ◽  
Viral Envelopes

scholarly journals Sendai virus recruits cellular villin to remodel actin cytoskeleton during fusion with hepatocytes

2017 ◽  
Vol 28 (26) ◽  
pp. 3801-3814 ◽  
Author(s):  
Sunandini Chandra ◽  
Raju Kalaivani ◽  
Manoj Kumar ◽  
Narayanaswamy Srinivasan ◽  
Debi P. Sarkar
Keyword(s):  
Membrane Fusion ◽  
Viral Entry ◽  
Sendai Virus ◽  
Viral Envelope ◽  
Bioactive Molecules ◽  
Host Cells ◽  
Actin Dynamics ◽  
Envelope Glycoproteins ◽  
Animal Cells ◽  
Viral Envelopes

Reconstituted Sendai viral envelopes (virosomes) are well recognized for their promising potential in membrane fusion–mediated delivery of bioactive molecules to liver cells. Despite the known function of viral envelope glycoproteins in catalyzing fusion with cellular membrane, the role of host cell proteins remains elusive. Here, we used two-dimensional differential in-gel electrophoresis to analyze hepatic cells in early response to virosome-induced membrane fusion. Quantitative mass spectrometry together with biochemical analysis revealed that villin, an actin-modifying protein, is differentially up-regulated and phosphorylated at threonine 206—an early molecular event during membrane fusion. We found that villin influences actin dynamics and that this influence, in turn, promotes membrane mixing through active participation of Sendai viral envelope glycoproteins. Modulation of villin in host cells also resulted in a discernible effect on the entry and egress of progeny Sendai virus. Taken together, these results suggest a novel mechanism of regulated viral entry in animal cells mediated by host factor villin.

Studies of membrane fusion. V. Fusion of erythrocytes with non-haemolytic Sendai virus

1979 ◽  
Vol 36 (1) ◽  
pp. 85-96
Author(s):  
S. Knutton
Keyword(s):  
Membrane Fusion ◽  
Cell Fusion ◽  
Erythrocyte Membrane ◽  
Sendai Virus ◽  
Lateral Diffusion ◽  
Viral Envelope ◽  
Cell Swelling ◽  
Viral Membrane ◽  
Cytoplasmic Bridges ◽  
Viral Envelopes

The fusion of human erythrocytes with non-haemolytic ‘1-day’ Sendai virus has been studied by electron microscopy. The mechanism of viral envelope-cell fusion is the same as that described previously for haemolytic ‘3-day’ Sendai virus except that fusion is frequently arrested at an initial stage when 2 segments of smooth linear viral membrane fuse and become incorporated into the erythrocyte membrane. After longer periods of incubation at 37 degrees C, in addition to many partly fused virus particles, long (up to 4 micrometer) lengths of smooth linear viral membrane are seen within the erythrocyte membrane which arise by linear aggregation of shorter (approximately 0.25 micrometer long) segments of smooth linear membrane derived from individual fused viral envelopes. Cell-Cell fusion, as a result of the fusion of a viral envelope with 2 adjacent erythrocytes also occurs but, in the absence of cell swelling, fusion is arrested at this stage with cells joined by one (or more) small cytoplasmic bridges. Typical fused cells are produced if such cells are swollen with hypotonic buffer. These observations provide further evidence that membrane fusion and cell swelling are distinct events in cell fusion and that cell swelling is the driving force both for completing the incorporation of the viral envelope into the cell membrane and for expanding cells connected by small cytoplasmic bridges to form spherical fused cells. Little lateral diffusion of viral envelope components occurs in the absence of cell swelling; in fact, some aggregation of components occurs. Comparison with previous studies using haemolytic ‘3-day’ Sendai virus suggests that virally induced cell swelling perturbs membrane structure so as to allow the rapid lateral diffusion of integrated viral envelope components.

scholarly journals Proinflammatory macrophage-derived microvesicles exhibit tumor tropism dependent on CCL2/CCR2 signaling axis and promote drug delivery via SNARE-mediated membrane fusion

Theranostics ◽  
2020 ◽  
Vol 10 (15) ◽  
pp. 6581-6598 ◽  
Author(s):  
Ling Guo ◽  
Ye Zhang ◽  
Runxiu Wei ◽  
Xiaochen Zhang ◽  
Cuifeng Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Membrane Fusion ◽  
Tumor Tropism ◽  
Signaling Axis

Progress in Membrane Fusion and Its Application in Drug Delivery

2019 ◽  
Vol 47 (12) ◽  
pp. 1871-1877
Author(s):  
Ying-Ying SU ◽  
Chun-Yan LI ◽  
Di LI
Keyword(s):  
Drug Delivery ◽  
Membrane Fusion

scholarly journals Histidylated Lipid-modified Sendai Viral Envelopes Mediate Enhanced Membrane Fusion and Potentiate Targeted Gene Delivery

2005 ◽  
Vol 280 (42) ◽  
pp. 35399-35409 ◽  
Author(s):  
Santosh K. Verma ◽  
Prashant Mani ◽  
Nishi Raj Sharma ◽  
Anuja Krishnan ◽  
Valluripalli Vinod Kumar ◽  
...  
Keyword(s):  
Gene Delivery ◽  
Membrane Fusion ◽  
Targeted Gene Delivery ◽  
Viral Envelopes

scholarly journals Virosomes: A groundbreaking revolution in novel drug delivery

2020 ◽  
Vol 11 (4) ◽  
pp. 5809-5820
Author(s):  
Sreeja C Nair ◽  
Sreelekshmi A S ◽  
Aslam Abdul Rahiman C A ◽  
Karthik Krishnan ◽  
Gopika G ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Nucleic Acids ◽  
Delivery System ◽  
Target Cells ◽  
Virus Like Particle ◽  
Unique System ◽  
Biomimetic Nanoparticles ◽  
Viral Envelopes ◽  
Or Genes ◽  
Novel Drug

The site-specific action of the drug has been seen from the last eras of the revolution in drug delivery technologies. Drug delivery opportunities by the use of biomimetic nanoparticles like virosomes is a stimulating area of research & development as it demonstrates targeted action by fusion with the target cell. Virosomes are vesicular particles reconstituted from viral envelopes which are non-replicating “artificial viruses” that denotes a unique system for presentation of antigen directly into the host cell. Trials have been created to use them as vaccines or adjuvants moreover as a delivery system for medicine, nucleic acids, or genes. Various attempts have been made to use them as vaccines or adjuvants as well as a delivery system for drugs, nucleic acids, or genes as they are biocompatible, biodegradable, non-toxic and non-autoimmunogenic. The production of vaccines increasingly moved away from living attenuated or inactivated whole organisms to safely killed organism. A virus that is safely killed can be a promising vector because it does not cause infection, and the viral structure allows the virosome to identify different components of its target cells. Pevion's virus-like particle (VLP) vaccine technology, called virosomes, and its architecture is specifically designed to produce safe and efficient vaccine subunits. Virosome-based vaccination is effective in reliable regulatory and safety records as well as the feasibility of upgrading production and has been approved in more than 40 countries, including infants and older people. The prospect of drug delivery and targeting using virosomes is a vital area of research and development. This review pinpoints the various aspect of virosome and will be a milestone for the researchers in the field of drug delivery.

Sign in / Sign up

Export Citation Format

Share Document